Datasheet is currently unavailable. Try again or CONTACT US
Stat2 Antibody
Mouse Monoclonal 19G8.H2.H6 IgG2a kappa
200-301-B65S
200-301-B65
25 µL
100 µg
Liquid (sterile filtered)
Liquid (sterile filtered)
WB, ELISA, IHC
Human
Mouse
Shipping info:
$50.00 to US & $70.00 to Canada for most products. Final costs are calculated at checkout.
Product Details
Anti-STAT2 (MOUSE) Monoclonal Antibody - 200-301-B65
mouse anti-STAT2 antibody, Stat 2, Signal transducer and activator of transcription 2, p113
Mouse
Monoclonal
IgG2a
Target Details
Stat2 - View All Stat2 Products
Human
Conjugated Peptide
This monoclonal antibody was produced by repeated immunizations with a synthetic peptide corresponding to residues near the carboxy terminus of mouse STAT2 protein.
This Protein-A purified antibody is directed against human STAT2 protein. A BLAST analysis was used to suggest cross-reactivity with STAT2 protein from human, rat (73%) and mouse (76%), sources based on homology with the immunizing sequence. Reactivity against homologues from other sources is not known.
Application Details
ELISA, IHC, WB
This Protein-A purified antibody has been tested for use in ELISA, immunohistochemistry, and western blotting. Specific conditions for reactivity should be optimized by the end user. Expect a band approximately 113 kDa in size corresponding to STAT2 protein by western blotting in the appropriate cell lysate or extract.
Formulation
1.0 mg/mL by UV absorbance at 280 nm
0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
0.01% (w/v) Sodium Azide
None
Shipping & Handling
Dry Ice
Store vial at -20° C prior to opening. Aliquot contents and freeze at -20° C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.
Expiration date is one (1) year from date of receipt.
STAT2 is a member of the STAT family of transcription factors. Unlike other STATs, STAT2 is unique as it can only be activated by interferons (IFNs). STAT2 is a critical component in mediating many IFN-stimulated biological activities including antiproliferation and antiviral responses. Upon IFN treatment, STAT1 and STAT2 become tyrosine phosphorylated, assemble as heterodimers that bind IRF9 to form the ISGF3 complex. This complex translocates to the nucleus, binds to promoters of IFN-stimulated genes and mediates gene transcription. Consequently, mutations in STAT2 or loss of STAT2 expression leads to impairment in IFN signal transduction and gene activation. IFN-alpha is an approved drug for the treatment of several forms of cancer. Yet only a subset of patients who receive IFN-alpha therapy benefit from the treatment. Given that STAT2 is activated by IFNs, it is important to define if the reduced or lack of antitumor effects seen in cancer patients on IFN therapy is due to in defects in STAT2 function. Our goal is to identify regions/motifs within the structural domains of STAT2 that not only are essential for the tyrosine phosphorylation of STAT2, but also regulate the antitumor effects of IFN-alpha. Collectively, the results of our studies will emphasize the physiological role of STAT2 in cancer. From a clinical viewpoint, cancer patients who may benefit the most from receiving IFN-alpha therapy can be selected based on their STAT2 function.
This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.